跳至主要内容
临床试验/ACTRN12614000783628
ACTRN12614000783628招募中3 期

Evaluation of Multiparametric Magnetic Resonance Imaging and Positron Emission Tomography with a [68Ga]gallium-labelled prostate-specific membrane antigen (PSMA) ligand for the Detection of Multiple Cancer Foci in Localized Prostate Cancer Patients – A Pilot Study

Queensland University of Technology0 个研究点目标入组 20 人开始时间: 2014年7月22日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • 1.Male patients pathologically diagnosed with localized prostate cancer, awaiting prostatectomy
  • 2. The time interval between last prostate biopsy and planned MP-MRI or planned 68Ga- HBED-CC PET must be not less than 8 weeks
  • 3. No known problems with peripheral intravenous or central line access
  • 4. Able to provide informed signed consent

排除标准

  • 1. Age under 18 years
  • 2. Prior pelvic external beam radiation therapy or brachytherapy, prior chemotherapy, prior hormonal or radiation therapy for prostate cancer
  • 3. Administered a radioisotope within 5 physical half-lives prior to study enrolment
  • 4. Treated with an investigational drug, investigational biologic, or investigational therapeutic device within 14 days prior to study radiotracer administration
  • 5. Hemorrhagic cystitis or active prostatitis
  • 6. Unable to lie flat during or unable to tolerate MP MRI or PET
  • 7. Prior history of any other malignancy within last 2 years
  • 8. Contraindication to MRI or MRI contrast agent or PET scan or [68Ga]gallium-labelled PSMA ligand
  • 9. Claustrophobia not manageable by oral sedatives ie Temazepam
  • 10. Moderate to severe rectal inflammation
  • 11. Previous rectal surgery that will affect prostate imaging
  • 12. MRI incompatible pacemakers
  • 13. Metallic implants or pumps which are MRI incompatible
  • 14. Renal impairment or hemodialysis.

研究者

相似试验

Evaluation of Multiparametric Magnetic Resonance... | 临床试验